<DOC>
	<DOCNO>NCT00003181</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Combining chemotherapy interleukin-2 GM-CSF may effective treatment kidney cancer . PURPOSE : Phase II trial study effectiveness low-dose interleukin-2 , vinblastine , GM-CSF treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Interleukin-2 , Vinblastine , GM-CSF Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) combination interleukin-2 vinblastine response rate patient metastatic renal cell carcinoma . II . Assess potential toxicity treatment combination patient . OUTLINE : This single arm , nonrandomized study . Patients receive vinblastine IV bolus every 2 week . Interleukin-2 administer subcutaneous injection day 1-5 week 9 week . Sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) administer subcutaneous injection day 1-5 week 9 week . Each 9 week cycle follow 3 week rest . Patient may continue treatment maximum 5 cycle absence disease progression . Patients assess every 12 week duration treatment . PROJECTED ACCRUAL : 20-35 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven inoperable , metastatic , recurrent renal cell carcinoma Measurable evaluable disease No brain metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : SWOG 02 Life expectancy : At least 3 month Hematopoietic : Neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Liver enzymes less 3 ( 5 know liver metastasis ) time institutional normal Renal : Creatinine le 1.5 mg/dL Cardiovascular : Adequate cardiac function No unstable angina No significant coronary artery disease No heart failure New York Heart Association classification III IV Pulmonary : No evidence pulmonary disease ( document normal DLCO PFT ) Other : No prior malignancy except : Nonmelanoma skin cancer Carcinoma situ kind No pregnant lactate Fertile patient must use adequate contraception Normal thyroid function evidence normal T4 TSH PRIOR CONCURRENT THERAPY : Biologic therapy : No 1 prior biologic therapy At least 4 week since prior biologic therapy Chemotherapy : No 1 prior chemotherapy At least 4 week since prior chemotherapy Endocrine therapy : No 1 prior hormonal therapy At least 4 week since prior hormonal therapy Radiotherapy : At least 4 week since prior radiation therapy No prior radiation therapy entire tumor within radiation field Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>